

Stephan N Wagner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9546888/publications.pdf>

Version: 2024-02-01

74
papers

13,578
citations

109264

35
h-index

74108

75
g-index

79
all docs

79
docs citations

79
times ranked

20159
citing authors

#	ARTICLE	IF	CITATIONS
1	Involvement of chemokine receptors in breast cancer metastasis. <i>Nature</i> , 2001, 410, 50-56.	13.7	4,837
2	A Landscape of Driver Mutations in Melanoma. <i>Cell</i> , 2012, 150, 251-263.	13.5	2,247
3	Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. <i>Nature</i> , 2005, 436, 117-122.	13.7	1,329
4	High-throughput oncogene mutation profiling in human cancer. <i>Nature Genetics</i> , 2007, 39, 347-351.	9.4	927
5	Melanoma genome sequencing reveals frequent PREX2 mutations. <i>Nature</i> , 2012, 485, 502-506.	13.7	671
6	Comparative Oncogenomics Identifies NEDD9 as a Melanoma Metastasis Gene. <i>Cell</i> , 2006, 125, 1269-1281.	13.5	380
7	B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. <i>Nature Communications</i> , 2019, 10, 4186.	5.8	236
8	Suppression of Nucleotide Metabolism Underlies the Establishment and Maintenance of Oncogene-Induced Senescence. <i>Cell Reports</i> , 2013, 3, 1252-1265.	2.9	228
9	Gene Expression Changes in an Animal Melanoma Model Correlate with Aggressiveness of Human Melanoma Metastases. <i>Molecular Cancer Research</i> , 2008, 6, 760-769.	1.5	216
10	Phase II Trial of a Toll-Like Receptor 9-Activating Oligonucleotide in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 5716-5724.	0.8	197
11	Integrative Genome Comparison of Primary and Metastatic Melanomas. <i>PLoS ONE</i> , 2010, 5, e10770.	1.1	166
12	Treatment of disseminated ocular melanoma with sequential fotemustine, interferon γ , and interleukin 2. <i>British Journal of Cancer</i> , 2002, 87, 840-845.	2.9	127
13	Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. <i>Nature Communications</i> , 2017, 8, 607.	5.8	109
14	Expression analysis of classic and non-classic HLA molecules before interferon alfa-2b treatment of melanoma. <i>Lancet, The</i> , 2000, 356, 220-221.	6.3	101
15	Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome. <i>Human Pathology</i> , 2016, 54, 157-164.	1.1	81
16	Downregulation of tapasin expression in progressive human malignant melanoma. <i>Archives of Dermatological Research</i> , 2003, 295, 43-49.	1.1	76
17	Targeting CD20 in Melanoma Patients at High Risk of Disease Recurrence. <i>Molecular Therapy</i> , 2012, 20, 1056-1062.	3.7	69
18	A slow-cycling subpopulation of melanoma cells with highly invasive properties. <i>Oncogene</i> , 2018, 37, 302-312.	2.6	65

#	ARTICLE	IF	CITATIONS
19	A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr). <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 453-467.	2.0	61
20	CpG Motifs Are Efficient Adjuvants for DNA Cancer Vaccines. <i>Journal of Investigative Dermatology</i> , 2004, 123, 371-379.	0.3	55
21	Digital image analysis improves precision of <sc>PD</sc>â€1 scoring in cutaneous melanoma. <i>Histopathology</i> , 2018, 73, 397-406.	1.6	54
22	Sites of urokinase-type plasminogen activator expression and distribution of its receptor in the normal human kidney. <i>Histochemistry and Cell Biology</i> , 1996, 105, 53-60.	0.8	53
23	MTSS1 is a metastasis driver in a subset of human melanomas. <i>Nature Communications</i> , 2014, 5, 3465.	5.8	52
24	Alterations of β -TA-p 73 splice transcripts during melanoma development and progression. <i>International Journal of Cancer</i> , 2004, 108, 162-166.	2.3	50
25	Macrophages in normal human bone marrow and in chronic myeloproliferative disorders: An immunohistochemical and morphometric study by a new monoclonal antibody (PG-M1) on trephine biopsies. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , 1992, 421, 33-39.	1.4	49
26	Combination of an EGFR blocker and a COXâ€2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma. <i>JDDG - Journal of the German Society of Dermatology</i> , 2008, 6, 1066-1069.	0.4	46
27	Homozygous deletion of the p16INK4a and the p15INK4b tumour suppressor genes in a subset of human sporadic cutaneous malignant melanoma. <i>British Journal of Dermatology</i> , 1998, 138, 13-21.	1.4	44
28	Inhibition of CRM1-Mediated Nucleocytoplasmic Transport: Triggering Human Melanoma Cell Apoptosis by Perturbing Multiple Cellular Pathways. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2780-2790.	0.3	43
29	NVP-LDE225, a Potent and Selective SMOOTHENED Antagonist Reduces Melanoma Growth In Vitro and In Vivo. <i>PLoS ONE</i> , 2013, 8, e69064.	1.1	42
30	Analysis of Pmel17/gp100 expression in primary human tissue specimens: implications for melanoma immuno- and gene-therapy. <i>Cancer Immunology, Immunotherapy</i> , 1997, 44, 239-247.	2.0	41
31	Unbalanced overexpression of the mutant allele in murine Patched mutants. <i>Carcinogenesis</i> , 2002, 23, 727-734.	1.3	40
32	Activated Neutrophils Exert Antitumor Activity Against Human Melanoma Cells: Reactive Oxygen Species-Induced Mechanisms and Their Modulation by Granulocyte-Macrophageâ€Colony-Stimulating Factor. <i>Journal of Investigative Dermatology</i> , 2003, 121, 936-938.	0.3	40
33	Lithium and psoriasis: cytokine modulation of cultured lymphocytes and psoriatic keratinocytes by lithium. <i>Archives of Dermatological Research</i> , 1996, 288, 173-178.	1.1	37
34	Differential downregulation of endoplasmic reticulum-residing chaperones calnexin and calreticulin in human metastatic melanoma. <i>Cancer Letters</i> , 2004, 203, 225-231.	3.2	36
35	HLA-G expression in malignant melanoma. <i>Seminars in Cancer Biology</i> , 2007, 17, 422-429.	4.3	36
36	Dual Suppression of the Cyclin-Dependent Kinase Inhibitors CDKN2C and CDKN1A in Human Melanoma. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1673-1679.	3.0	35

#	ARTICLE	IF	CITATIONS
37	Ras Gene Mutation: A Rare Event in Nonmetastatic Primary Malignant Melanoma. <i>Journal of Investigative Dermatology</i> , 1995, 104, 868-871.	0.3	33
38	Combining Filter-Aided Sample Preparation and Pseudoshotgun Technology To Profile the Proteome of a Low Number of Early Passage Human Melanoma Cells. <i>Journal of Proteome Research</i> , 2013, 12, 1040-1048.	1.8	33
39	A Standardized Analysis of Tertiary Lymphoid Structures in Human Melanoma: Disease Progression- and Tumor Site-Associated Changes With Germinal Center Alteration. <i>Frontiers in Immunology</i> , 2021, 12, 675146.	2.2	31
40	Immunoproteasome subunits LMP2 and LMP7 downregulation in primary malignant melanoma lesions. <i>Melanoma Research</i> , 2003, 13, 371-377.	0.6	30
41	Induction of Specific Immune Responses by Polycation-Based Vaccines. <i>Journal of Immunology</i> , 2002, 169, 5217-5226.	0.4	29
42	Association of TAP1 downregulation in human primary melanoma lesions with lack of spontaneous regression. <i>Melanoma Research</i> , 2003, 13, 253-258.	0.6	29
43	A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF. <i>Oncogene</i> , 2014, 33, 2531-2539.	2.6	29
44	Expression of Stromelysin 3 in the Stromal Elements of Human Basal Cell Carcinoma. <i>Diagnostic Molecular Pathology</i> , 1992, 1, 200-205.	2.1	28
45	Expression of Classic and Nonclassic HLA Class I Antigens in Uveal Melanoma. , 2003, 44, 2016.		24
46	Adjuvant treatment with vindesine in comparison to observation alone in patients with metastasized melanoma after complete metastasectomy: a randomized multicenter trial of the German Dermatologic Cooperative Oncology Group. <i>Melanoma Research</i> , 2008, 18, 353-358.	0.6	24
47	Polo-Like Kinase 1 Is a Potential Therapeutic Target in Human Melanoma. <i>Journal of Investigative Dermatology</i> , 2011, 131, 1886-1895.	0.3	23
48	Predominant Expression of CD44 Splice Variant v10 in Malignant and Reactive Human Skin Lymphocytes. <i>Journal of Investigative Dermatology</i> , 1998, 111, 464-471.	0.3	21
49	Tyrosine Phosphorylation in Psoriatic T Cells Is Modulated by Drugs That Induce or Improve Psoriasis. <i>Dermatology</i> , 1995, 191, 217-225.	0.9	20
50	The role of tumor microenvironment in melanoma therapy resistance. <i>Melanoma Management</i> , 2016, 3, 23-32.	0.1	18
51	Neuroendocrine neoplasms of the lung are not associated with point mutations at codon 12 of the Ki-ras gene. <i>Vigiliae Christianae</i> , 1993, 63, 325-329.	0.1	17
52	EMPACT syndrome. EMPACT-Syndrom. <i>JDDG - Journal of the German Society of Dermatology</i> , 2005, 3, 39-43.	0.4	17
53	Intracutaneous Genetic Immunization with Autologous Melanoma-Associated Antigen Pmel17/gp100 Induces T Cell-Mediated Tumor Protection In Vivo. <i>Journal of Investigative Dermatology</i> , 2000, 115, 1082-1087.	0.3	16
54	Growth Factors and Oncogenes as Targets in Melanoma: Lost in Translation?. <i>Advances in Dermatology</i> , 2007, 23, 99-129.	2.0	16

#	ARTICLE	IF	CITATIONS
55	Comprehensive Comparative and Semiquantitative Proteome of a Very Low Number of Native and Matched Epstein-Barr-Virus-Transformed B Lymphocytes Infiltrating Human Melanoma. <i>Journal of Proteome Research</i> , 2014, 13, 2830-2845.	1.8	15
56	Dual c-Jun N-terminal kinase-cyclin D1 and extracellular signal-related kinase-c-Jun disjunction in human melanoma. <i>British Journal of Dermatology</i> , 2016, 175, 1221-1231.	1.4	15
57	Megakaryocyte precursors (pro-and megakaryoblasts) in bone marrow tissue from patients with reactive thrombocytosis, polycythemia vera and primary (essential) thrombocythemia. <i>Vigiliae Christianae</i> , 1989, 58, 295-302.	0.1	14
58	Signal Sequence Receptor 2 is required for survival of human melanoma cells as part of an unfolded protein response to endoplasmic reticulum stress. <i>Mutagenesis</i> , 2016, 31, 573-582.	1.0	14
59	An Attempt at a Molecular Prediction of Metastasis in Patients with Primary Cutaneous Melanoma. <i>PLoS ONE</i> , 2012, 7, e49865.	1.1	13
60	TYPE-1 PLASMINOGEN ACTIVATOR INHIBITOR IN HUMAN RENAL CELL CARCINOMA. , 1996, 179, 95-99.		11
61	Hyaluronan-Independent Adhesion of CD44H+ and CD44v10+ Lymphocytes to Dermal Microvascular Endothelial Cells and Keratinocytes. <i>Journal of Investigative Dermatology</i> , 2001, 117, 949-957.	0.3	11
62	CD44 variant isoform v10 is expressed on tumor-infiltrating lymphocytes and mediates hyaluronan-independent heterotypic cell-cell adhesion to melanoma cells. <i>Experimental Dermatology</i> , 2003, 12, 204-212.	1.4	9
63	A Peptide to Reduce Pulmonary Edema in a Rat Model of Lung Transplantation. <i>PLoS ONE</i> , 2015, 10, e0142115.	1.1	8
64	Venous Leg Ulcers in a Patient with Klinefelter's Syndrome and Increased Activity of Plasminogen Activator Inhibitor-1. <i>Acta Dermato-Venereologica</i> , 2003, 83, 149-150.	0.6	6
65	Immunotargeting of tumor subpopulations in melanoma patients. <i>Onc Immunology</i> , 2012, 1, 1454-1456.	2.1	6
66	RanBP3 Regulates Melanoma Cell Proliferation via Selective Control of Nuclear Export. <i>Journal of Investigative Dermatology</i> , 2016, 136, 264-274.	0.3	6
67	Loss of Lymphotoxin Alpha-Expressing Memory B Cells Correlates with Metastasis of Human Primary Melanoma. <i>Diagnostics</i> , 2021, 11, 1238.	1.3	6
68	Induction of Targeted Cell Migration by Cutaneous Administration of a DNA Vector Encoding a Biologically Active Chemokine CCL21. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1611-1623.	0.3	4
69	Spatiotemporal Analysis of B Cell- and Antibody Secreting Cell-Subsets in Human Melanoma Reveals Metastasis-, Tumor Stage-, and Age-Associated Dynamics. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 677944.	1.8	3
70	Lithium and psoriasis: cytokine modulation of cultured lymphocytes and psoriatic keratinocytes by lithium. <i>Archives of Dermatological Research</i> , 1996, 288, 173-178.	1.1	3
71	Epithelioid Sarcoma: A Frequently Misdiagnosed Neoplasm. <i>Acta Dermato-Venereologica</i> , 2001, 81, 139-140.	0.6	2
72	Î³ T-cell Lymphoma Mimicking S�zary Syndrome. <i>Acta Dermato-Venereologica</i> , 2012, 92, 166-168.	0.6	2

#	ARTICLE	IF	CITATIONS
73	Anaphylactic reaction to carboplatin diagnosed by skin testing – a reliable tool in platinum-based immediate-type hypersensitivity reactions. Wiener Medizinische Wochenschrift, 2023, 173, 256-259.	0.5	2
74	Kombination eines EGFR-Blockers mit einem COX-2-Inhibitor für die Behandlung des fortgeschrittenen kutanen Plattenepithelkarzinoms. JDDG - Journal of the German Society of Dermatology, 2008, 6, no.	0.4	0